Does Pharma Have a Duty to Innovate? The Law Says No But..

Scientist in lab coat working at lab bench with illuminated data network overlay

On August 3, 2026, the California Supreme Court unanimously ruled that pharma companies have no legal duty to improve drugs. By a vote of 6–1, the court decided that drug companies do not have a legal “duty to innovate,” or a duty to develop/commercialize a safer version of an approved drug faster. Good for pharma, but patients see it another way.

This ruling came from a lawsuit against Gilead Sciences’ HIV treatments. The plaintiffs claimed that Gilead intentionally postponed releasing an updated version (TAF), with less kidney and bone toxicity compared to the original version (TDF), to prolong sales of the original drug. Around 24,000 patients attempted to sue the company for injuries they claimed to have suffered as a result. The Court dismissed those lawsuits

The Court’s Reasoning

Justice Joshua Groban authored the majority opinion, finding that under California negligence law, a manufacturer owes no duty to develop an alternative medicine where its current product is safe, FDA-approved, and not defective under law.

The Court continued with the observation that imposing such a duty “would have alarming unintended consequences. It would permit juries to second-guess decades of scientific and commercial judgments. It would subject companies to essentially limitless liability for their research priorities. It could stifle innovation in the pharma industry by exposing companies to litigation risk every time they make a decision about research and development.”

From a strictly legal standpoint, this ruling makes sense. Tort law has traditionally

But Law and Ethics Are Not the Same

Just because there is no legal obligation does not mean there is no ethical one. Pharmaceutical companies today receive tremendous advantages: Exclusive patents, regulatory security, pricing that far exceeds the cost of research and production for new therapies. Public taxpayer funding of basic science through the NIH; tax breaks to develop drugs. There is one reason for all of these things: we want them to continually innovate and improve drugs to help patients. If we have reason to believe that a therapy can be made substantially safer, patients should expect companies to go to great lengths to do so.

Innovation Is More Than Discovering New Molecules

Big Pharma tends to equate innovation with first-in-class science. Patients have a different definition of innovation. To patients, innovation is: Fewer adverse events, better adherence, easier dosing, improved quality of life, longer survival

What This Means for Medical Affairs

The ruling also underscores another trend we are seeing: the increasing strategic value of Medical Affairs organizations. MSLs, medical directors, and evidence-generation teams are on the front lines when it comes to discovering gaps after launch.

By engaging in scientific dialogue with HCPs, they can gather real-world data on safety, tolerability, adherence, and patient outcomes that may help to prioritize future studies. While there may not be a legal mandate to innovate, Medical Affairs teams can position their organizations to see where innovation is required next. Innovation doesn’t stop at FDA approval. It should continue well into a product’s lifecycle.

The Strategic Risk

The Court eliminated one source of legal liability. It did not eliminate market expectations. Physicians increasingly demand continuous evidence generation. Patients expect therapies to become safer as time goes on. Payers are increasingly assessing comparative clinical value rather than simply approving new products. Companies that do not continue to develop their medicines risk losing scientific credibility, physician confidence, and competitive advantage despite avoiding courtroom liability.

The California Supreme Court answered a legal question:

No, pharmaceutical companies do not currently have a legal duty to innovate.

The industry must still answer the harder question:

If innovation is the reason society grants patents, exclusivity, and premium pricing, shouldn’t continuous innovation be viewed as part of the responsibility that accompanies those privileges?

The law says companies cannot generally be forced to innovate. Patients—and ultimately the market—may decide that companies who choose not to innovate pay a different price.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply